Cover Image
Market Research Report

North America Cephalosporin Drugs Market (2019-2025)

Published by KBV Research Product code 906239
Published Content info 98 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Cephalosporin Drugs Market (2019-2025)
Published: July 31, 2019 Content info: 98 Pages
Description

The North America Cephalosporin Drugs Market would witness market growth of 4.69% CAGR during the forecast period (2019-2025). Market growth is driven by the implementation of combination drugs like various antibacterials or antibacterials coupled with an inhibitor. It is anticipated that the use of combination drugs will reduce the likelihood of developing antibiotic-resistant bacterial strains, which is supposed to boost the market growth.

Compared to the first and second generations, Cephalosporin Drugss of the third generation are more efficient against Gram-negative bacteria. They are also more effective against bacteria that can be resistant to prior Cephalosporin Drugs generations. Cefepime (Maxipime) is the only Cephalosporin Drugs of the fourth generation accessible in the U.S. Although it is efficient against a multitude of Gram-positive and Gram-negative organisms, it is generally reserved for more serious diseases. The fifth-generation Cephalosporin Drugs, ceftaroline (Teflaro) may be used to treat bacteria that are resistant to penicillin antibiotics, including resistant species Staphylococcus aureus (MRSA) and Streptococcus.

Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.

Scope of the Study

Market Segmentation:

By Generation

  • First-Generation Cephalosporin
  • Second-Generation Cephalosporin
  • Third-Generation Cephalosporin
  • Fourth-Generation Cephalosporin
  • Fifth-Generation Cephalosporin

By Application

  • Respiratory Tract Infection
  • Skin Infection
  • Ear Infection
  • Sexually Transmitted Infection
  • Others

By Route of Administration

  • Injections
  • Oral Drugs

By Type

  • Branded
  • Generic

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Companies Profiled:

  • ABBOTT Laboratories
  • Teva Pharmaceuticals Industries Ltd.
  • Johnson and Johnson
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • Baxter International, Inc.
  • BRISTOL-MYERS SQUIBB COMPANY
  • Novartis AG

Unique Offerings from KBV Research:

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 North America Cephalosporin Drugs Market, by Generation
    • 1.4.2 North America Cephalosporin Drugs Market, by Application
    • 1.4.3 North America Cephalosporin Drugs Market, by Route of Administration
    • 1.4.4 North America Cephalosporin Drugs Market, by Type
    • 1.4.5 North America Cephalosporin Drugs Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. North America Cephalosporin Drugs Market by Generation

  • 3.1 North America First-Generation Cephalosporin Drugs Market by Country
  • 3.2 North America Second-Generation Cephalosporin Drugs Market by Country
  • 3.3 North America Third-Generation Cephalosporin Drugs Market by Country
  • 3.4 North America Fourth-Generation Cephalosporin Drugs Market by Country
  • 3.5 North America Fifth-Generation Cephalosporin Drugs Market by Country

Chapter 4. North America Cephalosporin Drugs Market by Application

  • 4.1 North America Respiratory Tract Infection Market by Country
  • 4.2 North America Skin Infection Market by Country
  • 4.3 North America Ear Infection Market by Country
  • 4.4 North America Sexually Transmitted Infection Market by Country
  • 4.5 North America Others Market by Country

Chapter 5. North America Cephalosporin Drugs Market by Route of Administration

  • 5.1 North America Injections Market by Country
  • 5.2 North America Oral Drugs Market by Country

Chapter 6. North America Cephalosporin Drugs Market by Type

  • 6.1 North America Branded Market by Country
  • 6.2 North America Generic Market by Country

Chapter 7. North America Cephalosporin Drugs Market by Country

  • 7.1 USA Cephalosporin Drugs Market
    • 7.1.1 USA Cephalosporin Drugs Market by Generation
    • 7.1.2 USA Cephalosporin Drugs Market by Application
    • 7.1.3 USA Cephalosporin Drugs Market by Route of Administration
    • 7.1.4 USA Cephalosporin Drugs Market by Type
  • 7.2 Canada Cephalosporin Drugs Market
    • 7.2.1 Canada Cephalosporin Drugs Market by Generation
    • 7.2.2 Canada Cephalosporin Drugs Market by Application
    • 7.2.3 Canada Cephalosporin Drugs Market by Route of Administration
    • 7.2.4 Canada Cephalosporin Drugs Market by Type
  • 7.3 Mexico Cephalosporin Drugs Market
    • 7.3.1 Mexico Cephalosporin Drugs Market by Generation
    • 7.3.2 Mexico Cephalosporin Drugs Market by Application
    • 7.3.3 Mexico Cephalosporin Drugs Market by Route of Administration
    • 7.3.4 Mexico Cephalosporin Drugs Market by Type
  • 7.4 Rest of North America Cephalosporin Drugs Market
    • 7.4.1 Rest of North America Cephalosporin Drugs Market by Generation
    • 7.4.2 Rest of North America Cephalosporin Drugs Market by Application
    • 7.4.3 Rest of North America Cephalosporin Drugs Market by Route of Administration
    • 7.4.4 Rest of North America Cephalosporin Drugs Market by Type

Chapter 8. Company Profiles

  • 8.1 ABBOTT Laboratories
    • 8.1.1 Company Overview
    • 8.1.2 Financial Analysis
    • 8.1.3 Segmental and Regional Analysis
    • 8.1.4 Research & Development Expense
    • 8.1.1 Recent strategies and developments:
      • 8.1.1.1 Collaborations, partnerships and agreements:
      • 8.1.1.2 Acquisition and Mergers:
  • 8.2 Teva Pharmaceutical Industries Ltd.
    • 8.2.1 Company Overview
    • 8.2.2 Financial Analysis
    • 8.2.3 Regional Analysis
    • 8.2.4 Research & Development Expenses
    • 8.2.5 Recent strategies and developments:
      • 8.2.5.1 Product launches:
  • 8.3 Johnson and Johnson
    • 8.3.1 Company Overview
    • 8.3.2 Financial Analysis
    • 8.3.3 Segmental &Regional Analysis
    • 8.3.4 Research & Development Expenses
    • 8.3.5 Recent strategies and developments:
      • 8.3.5.1 Acquisition and Mergers:
  • 8.4 GlaxoSmithKline PLC (GSK)
    • 8.4.1 Company Overview
    • 8.4.2 Financial Analysis
    • 8.4.3 Segmental and Regional Analysis
    • 8.4.4 Research & Development Expense
    • 8.4.5 Recent strategies and developments:
      • 8.4.5.1 Collaborations, partnerships and agreements:
      • 8.4.5.2 Expansion:
      • 8.4.5.3 Approval:
  • 8.5 Pfizer, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Analysis
    • 8.5.3 Segmental and Regional Analysis
    • 8.5.4 Research & Development Expense
    • 8.5.5 Recent strategies and developments:
      • 8.5.5.1 Collaborations, partnerships and agreements:
      • 8.5.5.2 Product launches:
      • 8.5.5.3 Acquisition and Mergers:
  • 8.6 Merck & Co., Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Financial Analysis
    • 8.6.3 Segmental and Regional Analysis
    • 8.6.4 Research & Development Expenses
    • 8.6.5 Recent strategies and developments:
      • 8.6.5.1 Collaborations, partnerships and agreements:
      • 8.6.5.2 Product launches:
  • 8.7 Bayer AG (Bayer Schering Pharma AG)
    • 8.7.1 Company Overview
    • 8.7.2 Financial Analysis
    • 8.7.3 Segmental and Regional Analysis
    • 8.7.4 Research & Development Expense
    • 8.7.5 Recent strategies and developments:
      • 8.7.5.1 Collaborations, partnerships and agreements:
      • 8.7.5.2 Product launches:
  • 8.8 Baxter International, Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Financial Analysis
    • 8.8.3 Regional Analysis
    • 8.8.4 Research & Development Expense
    • 8.8.5 Recent strategies and developments:
      • 8.8.5.1 Product launches:
  • 8.9 Bristol-Myers Squibb Company
    • 8.9.1 Company overview
    • 8.9.2 Financial Analysis
    • 8.9.3 Regional Analysis
    • 8.9.4 Research & Development Expense
    • 8.9.5 Recent strategies and developments:
      • 8.9.5.1 Collaborations, partnerships and agreements:
  • 8.1 Novartis AG
    • 8.10.1 Company Overview
    • 8.10.2 Financial Analysis
    • 8.10.3 Segmental and Regional Analysis
    • 8.10.4 Research & Development Expense
    • 8.10.5 Recent strategies and developments:
      • 8.10.5.1 Product launches:
      • 8.10.5.2 Acquisition and Mergers:

LIST OF TABLES

  • TABLE 1 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 2 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 3 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 4 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 5 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 6 NORTH AMERICA FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 7 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 8 NORTH AMERICA SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 9 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 10 NORTH AMERICA THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 11 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 12 NORTH AMERICA FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 13 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 14 NORTH AMERICA FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 15 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 16 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 17 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 18 NORTH AMERICA RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 19 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 20 NORTH AMERICA SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 21 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 22 NORTH AMERICA EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 23 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 24 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 25 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 26 NORTH AMERICA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 27 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 28 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 29 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 30 NORTH AMERICA INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 31 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 32 NORTH AMERICA ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 33 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 34 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 35 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 36 NORTH AMERICA BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 37 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 38 NORTH AMERICA GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 39 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 40 NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 41 USA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 42 USA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 43 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 44 USA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 45 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 46 USA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 47 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 48 USA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 49 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 50 USA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 51 CANADA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 52 CANADA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 53 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 54 CANADA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 55 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 56 CANADA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 57 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 58 CANADA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 59 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 60 CANADA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 61 MEXICO CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 62 MEXICO CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 63 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 64 MEXICO CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 65 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 66 MEXICO CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 67 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 68 MEXICO CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 69 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 70 MEXICO CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 71 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
  • TABLE 72 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
  • TABLE 73 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
  • TABLE 74 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
  • TABLE 75 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
  • TABLE 76 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
  • TABLE 77 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
  • TABLE 78 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
  • TABLE 79 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
  • TABLE 80 REST OF NORTH AMERICA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
  • TABLE 81 KEY INFORMATION - ABBOTT LABORATORIES
  • TABLE 82 KEY INFORMATION - TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • TABLE 83 KEY INFORMATION -JOHNSON AND JOHNSON
  • TABLE 84 KEY INFORMATION - GLAXOSMITHKLINE PLC (GSK)
  • TABLE 85 KEY INFORMATION - PFIZER, INC.
  • TABLE 86 KEY INFORMATION - MERCK & CO., INC.
  • TABLE 87 KEY INFORMATION - BAYER AG
  • TABLE 88 KEY INFORMATION - BAXTER INTERNATIONAL, INC.
  • TABLE 89 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 90 KEY INFORMATION - NOVARTIS AG

LIST OF FIGURES

  • FIG 1 METHODOLOGY FOR THE RESEARCH
Back to Top